JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
申请人:Wuhan LL Science and Technology Development Co.,
Ltd.
公开号:EP4023642A1
公开(公告)日:2022-07-06
Provided are a compound as shown in formula (I), which formula is as follows, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof, wherein same can be used as JNK inhibitors. Also provided are a method for preparing the compound shown in formula (I), a pharmaceutical composition comprising the compound shown in formula (I), and the use of the compound shown in formula (I) for preparing drugs, wherein the drugs are used for treating diseases which can be treated by inhibiting JNK activity.
[EN] JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] INHIBITEUR DE JNK, ET COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE<br/>[ZH] JNK抑制剂、其药物组合物和用途
[EN] INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE<br/>[FR] COMPOSÉS D'INDAZOLE PERMETTANT D'ACTIVER LA GLUCOKINASE
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2008156757A1
公开(公告)日:2008-12-24
[EN] The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. A compound represented by the formula (I): wherein R1, R2, R3, R4 are as defined herein; or a salt thereof. [FR] La présente invention a pour objet un activateur de la glucokinase utile en tant qu'agent pharmaceutique, tel qu'un agent pour la prophylaxie ou le traitement du diabète, de l'obésité et d'autres maladies similaires. Un composé représenté par la formule (I): où R1, R2, R3, R4 sont tels que définis dans la description ; ou un sel de ceux-ci.